Coronavirus disease 2019 subphenotypes and differential treatment response to convalescent plasma in critically ill adults: secondary analyses of a randomized clinical trial.
M FishJ RynneA JenningsC LamA A LamikanraJ RatcliffS Cellone-TrevelinE TimmsJ JirihaI TosiR PramanikP SimmondsS SethJ WilliamsA C GordonJ KnightD J SmithJ WhalleyD HarrisonK RowanH HarvalaP KlenermanL EstcourtD K MenonD RobertsManu Shankar-Harinull nullPublished in: Intensive care medicine (2022)
We reported three COVID-19 subphenotypes, among critically ill adults, with differential treatment effects to ABO-compatible convalescent plasma therapy. Differences in subphenotype prevalence between RCT populations probably explain inconsistent results with COVID-19 immunotherapies.